Rivus Pharmaceuticals will present preclinical primate and rodent data at ObesityWeek 2026 for RV-8451, an oral small-molecule GLP-1 receptor agonist reported to produce fat-selective weight loss while preserving lean mass. Abstracts include a head-to-head comparison against orforglipron and a mouse study in which RV-8451 reversed orforglipron-associated lean mass loss. An investigational new drug application is planned for the first quarter of 2027, with Phase 1 testing to follow.
Key Points
- Oral GLP-1 agonist RV-8451 reported fat-selective in preclinical obesity models
- Reversed lean mass loss induced by orforglipron in mice
- Data remain preclinical; IND filing targeted for early 2027
Longevity Analysis
Lean mass is a primary determinant of metabolic rate, glucose disposal, fall resistance and functional independence across the later decades, which makes the composition of weight lost more consequential than the magnitude. Pharmacological approaches that spare contractile tissue while reducing adipose burden would alter the risk calculus of incretin therapy for older adults, though nonhuman primate and rodent results frequently fail to translate. Interpreting body composition rather than scale weight — and pairing any such agent with resistance loading and adequate protein — remains the practical determinant of outcome.
Original published by LT Wire.